Nonalcoholic fatty liver disease in type 2 diabetes: A bad omen. But can we do something to change it?

References

[1] Younossi ZM,Racila A.Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S.Diabetes Care2020;43:283-9

[2] Centers for Medicare & Medicaid Services. National Health Expenditures 2019 Highlights. Available at: https://www.cms.gov/files/document/highlights.pdf. [Last accessed on 17 Aug 2021]

[3] Rinella ME,Loomba R.Practice patterns in NAFLD and NASH: real life differs from published guidelines.Therap Adv Gastroenterol2016;9:4-12 PMCID:PMC4699276

[4] Cusi K,Bril F.Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.Ann Intern Med2016;165:305-15

[5] Newsome PN,Cusi K.A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.N Engl J Med2021;384:1113-24

[6] Younossi ZM,Loomba R.REGENERATE Study InvestigatorsObeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.Lancet2019;394:2184-96

[7] Sanyal AJ,Kowdley KV.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.N Engl J Med2010;362:1675-85 PMCID:PMC2928471